DEXCOM INC
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Dexcom (DXCM) released its 2026 State of Type 2 Report, highlighting the gap in CGM awareness and access. 89% of HCPs see CGM as essential, but 55% of patients lack knowledge. Dexcom also partnered with Team Novo Nordisk as its official CGM partner, aiming to advance diabetes care and awareness.
DexCom (DXCM) promoted its CFO, Jereme Sylvain, to also serve as COO, expanding his role to include global operations and quality. The company's stock has seen volatility, with a 3.1% drop over the past week and a 30.2% gain year-to-date. Analysts suggest a fair value of $94.48, indicating a modest discount at the current price of $86.62.
DexCom (DXCM) has promoted former CFO Jereme Sylvain to the role of Chief Operating Officer. The announcement highlights a leadership change at the company, which may impact investor perception.
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning DXCM (DEXCOM INC). Coverage has skewed bullish: 1 bullish, 2 neutral, and 0 bearish.
Recent DXCM coverage spans financial news, corporate actions and insider activity.
In the last 30 days, DXCM insiders filed 4 SEC Form 4 transactions — no purchases and 4 sales ($1.1M). The most active reporter was AUGUSTINOS NICHOLAS with 2 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
The partnership and report highlight growth opportunities in the Type 2 diabetes market, likely generating modest positive sentiment for Dexcom.
The dual CFO/COO appointment adds execution risk and may tighten margins, leading to modest downside pressure.
Leadership change may affect operational execution and investor perception.
The leadership changes could improve operational efficiency and investment discipline, but the impact on near-term price is uncertain.
Executive reshuffle may improve operational oversight but adds uncertainty about strategic direction.
AlphAI scores every news story that mentions DXCM with an AI model for sentiment and relevance, and aggregates insider trades from DEXCOM INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Dexcom (DXCM) released its 2026 State of Type 2 Report, highlighting the gap in CGM awareness and access. 89% of HCPs see CGM as essential, but 55% of patients lack knowledge. Dexcom also partnered with Team Novo Nordisk as its official CGM partner, aiming to advance diabetes care and awareness.
2 min readDexCom (DXCM) promoted its CFO, Jereme Sylvain, to also serve as COO, expanding his role to include global operations and quality. The company's stock has seen volatility, with a 3.1% drop over the past week and a 30.2% gain year-to-date. Analysts suggest a fair value of $94.48, indicating a modest discount at the current price of $86.62.
2 min readDexCom (DXCM) has promoted former CFO Jereme Sylvain to the role of Chief Operating Officer. The announcement highlights a leadership change at the company, which may impact investor perception.
1 min readDexCom (DXCM) appointed Jereme Sylvain as COO and Glenn Boehnlein to its board, focusing on execution, supply chain, and capital allocation. The company projects $6.8B revenue and $1.5B earnings by 2029, with analysts expecting 11.2% yearly growth. Investors watch leadership changes for impact on expansion and execution.
2 min readDexCom (DXCM) promoted CFO Jereme Sylvain to CFO and COO, added Glenn S. Boehnlein to its board. The stock trades at $87.93, up 21.33% over 90 days and 32.15% year-to-date. Analysts estimate fair value at $94.12, with growth driven by expanded insurance coverage and global market penetration. The company trades at a P/E of 33.2x, above sector and peer averages.
2 min readAUGUSTINOS NICHOLAS sold 8,089 indirectly-held shares of DEXCOM INC (DXCM) at an average of $84.04 ($84.02–$84.04, $0.68M total) across 2 trades over 2026-09-14 to 2026-09-15 under a Rule 10b5-1 trading plan.
1 min readDexcom Inc. (DXCM) promoted CFO Jereme Sylvain to COO, overseeing global operations and quality. Sylvain joined in 2018, became CFO in 2021. CEO Jake Leach cited his strategic judgment and operational discipline. Shares closed at $84.68, up 1.99%.
1 min readDEXCOM INC (DXCM) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Dexcom Promotes Jereme Sylvain to Chief Operating Officer SAN DIEGO - (BUSINESS WIRE- September 14, 2026) - DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the promotion of Jereme Sylvain to the role of Chief Operating Officer (CO
1 min readResMed (RMD) and peers reported Q2 earnings, with revenues beating estimates by 1.4% but next quarter's guidance below. RMD's revenue grew 8.6% YoY, meeting expectations, while iRhythm (IRTC) saw 20.1% growth, exceeding estimates. Insulet (PODD) and DexCom (DXCM) also reported, with mixed results. Stocks have declined since earnings, with RMD down 2.3% and IRTC down 13%.
3 min readDexCom, Inc. will add Glenn Boehnlein to its Board of Directors on September 10, 2026. Boehnlein, a healthcare executive, previously served as CFO of Stryker Corporation and holds board positions at Inogen, Inc. and Agilent Technologies, Inc. He brings financial and strategic expertise to DexCom.
1 min read
